Apellis Pharma Reports Executive Changes & Comp Arrangements
Ticker: APLS · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1492422
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Apellis just filed an 8-K about executive changes and pay, keep an eye on leadership shifts.**
AI Summary
Apellis Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, reporting events from January 16, 2024, related to changes in its executive team and compensation arrangements. This filing indicates potential shifts in leadership or strategic direction, which could impact the company's future performance and investor confidence. For shareholders, understanding these changes is crucial as new leadership often brings new strategies that can affect stock value.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or internal restructuring, directly influencing a company's operational efficiency and future growth prospects.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company strategy and performance, posing a medium risk to investors.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and their potential impact on Apellis's strategic direction and operational performance.
Key Numbers
- 001-38276 — Commission File Number (Identifies Apellis Pharmaceuticals, Inc. with the SEC)
- 100 Fifth Avenue, Waltham, MA, 02451 — Business Address (Primary location of Apellis Pharmaceuticals, Inc.)
- (617) 977-5700 — Business Phone Number (Contact information for Apellis Pharmaceuticals, Inc.)
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Apellis's Common Stock (APLS) is registered
- 001-38276 (dollar_amount) — Commission File Number for Apellis Pharmaceuticals, Inc.
- January 16, 2024 (date) — Date of earliest event reported in the 8-K
- January 22, 2024 (date) — Date the 8-K was filed
Forward-Looking Statements
- Apellis Pharmaceuticals, Inc. will likely provide more detailed information about the specific executive changes and compensation arrangements in future filings or press releases. (Apellis Pharmaceuticals, Inc.) — high confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 16, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 22, 2024, as indicated by the 'FILED AS OF DATE' and 'ACCESSION NUMBER' information.
What specific items are covered in this 8-K filing for Apellis Pharmaceuticals, Inc.?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' under Item Information.
On which stock exchange is Apellis Pharmaceuticals, Inc.'s Common Stock traded?
Apellis Pharmaceuticals, Inc.'s Common Stock (APLS) is registered on the Nasdaq Global Select Market, as specified under 'Name of each exchange on which registered'.
What is the business address and phone number of Apellis Pharmaceuticals, Inc. as listed in the filing?
The business address for Apellis Pharmaceuticals, Inc. is 100 Fifth Avenue, Waltham, MA, 02451, and their telephone number is (617) 977-5700, according to the filing's 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-01-22 08:00:55
Filing Documents
- d696780d8k.htm (8-K) — 23KB
- 0001193125-24-011699.txt ( ) — 138KB
- apls-20240116.xsd (EX-101.SCH) — 3KB
- apls-20240116_lab.xml (EX-101.LAB) — 17KB
- apls-20240116_pre.xml (EX-101.PRE) — 11KB
- d696780d8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 16, 2024, the Board of Directors of Apellis Pharmaceuticals, Inc. (the "Company") appointed Adam Townsend, the Company's Chief Commercial Officer, to serve as the Company's Chief Operating Officer, effective immediately. Mr. Townsend, 47, has served as the Company's Chief Commercial Officer since November 2018. From March 2010 to October 2018 he served in a variety of leadership roles at Biogen, including as Senior Vice President of Corporate Development from March 2018 to October 2018, as Senior Vice President, Specialty Medicines and Rare Disease Group from April 2017 to March 2018, as Vice President, Asset Executive for Spinraza from May 2016 to April 2017, Vice President – Account Executive for Hemophilia from November 2015 to May 2016, and Vice President Global Marketing – Head of Multiple Sclerosis from July 2013 to November 2015. Mr. Townsend received his medical biochemistry degree from Royal Holloway, University of London. Mr. Townsend has no family relationships with any of the Company's directors or executive officers. There are no transactions and no proposed transactions between Mr. Townsend and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apellis Pharmaceuticals, Inc. Date: January 22, 2024 By: /s/ Timothy Sullivan Timothy Sullivan Chief Financial Officer